BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Seattle Genetics, Inc. 

21823 - 30th Drive S.E.

Bothell  Washington  98021  U.S.A.
Phone: 425-527-4000 Fax: 425-527-4001


SEARCH JOBS
Committed to improving patient outcomes
At Seattle Genetics, we are committed to developing innovative antibody-based therapies that improve clinical outcomes for patients with cancer and autoimmune diseases. We are dedicated to addressing unmet medical need, and strive to achieve that goal through an unwavering commitment to excellence in clinical development.

Focusing on Clinical Development
Seattle Genetics is a clinical stage biotechnology company advancing a broad product pipeline of antibody-based therapies. Our lead program, brentuximab vedotin (SGN-35), is in a pivotal trial under a Special Protocol Assessment with the FDA for patients with relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is empowered by Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. In addition, we are conducting clinical trials with four other product candidates, lintuzumab (SGN-33), dacetuzumab (SGN-40) and SGN-75, for the treatment of cancer, and SGN-70, for autoimmune diseases. We are also advancing a pipeline of promising preclinical candidates and have robust research and development capabilities that are our engine for innovation and long-term growth.

Our proprietary ADC technology empowers antibodies by stably linking them to cell-killing drug payloads. The drug payload is inactive until released from the antibody inside the targeted cancer cell, thereby sparing normal tissue the toxicity of traditional chemotherapy. In addition to brentuximab vedotin, SGN-75 is an ADC that is in a phase I clinical trial and we are developing several preclinical ADC product candidates, including ASG-5ME, which is advancing towards a planned 2010 clinical trial for solid tumors.

Expanding Our Opportunities Through Collaboration
Collaborating with leading biopharmaceutical companies is a cornerstone of Seattle Genetics' business strategy. Product-focused collaborations, such as our exclusive worldwide collaboration agreement with Genentech (a wholly owned member of the Roche Group) to develop and commercialize dacetuzumab, provide significant near- and mid-term funding while bringing in additional resources and expertise to support, advance and expand promising development programs. Collaboration and license agreements around our proprietary ADC technology also generate cash for the company - more than $75 million to date - while providing further clinical validation of the ADC platform and, in some cases, opening the door to new product development opportunities.


 Key Statistics


Email: contact@seagen.com
Ownership: Public

Web Site: Seattle Genetics, Inc.
Employees:
Symbol: SGEN
 



Industry
Biotechnology


Collaborations

Celera Corporation  Seeking to jointly discover and develop antibody-based therapies for cancer.

Applied Molecular Evolution/Eli Lilly 

MedImmune 





 Company News
Seattle Genetics, Inc. (SGEN) To Host Conference Call And Webcast Discussion Of First Quarter 2014 Financial Results On May 1, 2014 4/16/2014 7:22:47 AM    More...
Seattle Genetics, Inc. (SGEN) Achieves Milestones Under Collaboration With Takeda Pharmaceutical Co. Ltd. (TKPYY) For Achieving First Commercial Sales Of ADCETRIS® (Brentuximab Vedotin) In Key Countries 4/8/2014 8:48:21 AM    More...
Seattle Genetics, Inc. (SGEN) Highlights Antibody-Drug Conjugate (ADC) Program And Technology Advances At American Association for Cancer Research 4/7/2014 8:57:52 AM    More...
Seattle Genetics, Inc. (SGEN) Highlights ADCETRIS® (Brentuximab Vedotin) Clinical Data At The 2014 Bone Marrow Transplant Tandem Meetings 2/27/2014 9:55:05 AM    More...
Seattle Genetics, Inc. (SGEN) Reports Fourth Quarter And Year 2013 Financial Results 2/12/2014 8:23:52 AM    More...
Seattle Genetics, Inc. (SGEN) Announces Executive Promotions And Management Addition 2/10/2014 9:45:06 AM    More...
Seattle Genetics, Inc. (SGEN) Achieves Sales Milestone Under ADCETRIS® (Brentuximab Vedotin) Collaboration With Takeda Pharmaceutical Co. Ltd. (TKPYY) 2/5/2014 7:35:19 AM    More...
Seattle Genetics, Inc. (SGEN) To Host Conference Call And Webcast Discussion Of Fourth Quarter And Year 2013 Financial Results On February 11, 2014 1/23/2014 7:25:39 AM    More...
Seattle Genetics, Inc. (SGEN) Announces ADCETRIS® (Brentuximab Vedotin) Approval In Japan For The Treatment Of Relapsed Or Refractory Hodgkin Lymphoma And Anaplastic Large Cell Lymphoma 1/17/2014 7:09:49 AM    More...
Seattle Genetics, Inc. (SGEN) Appoints John A. Orwin To Board Of Directors 1/13/2014 7:26:00 AM    More...
12345678910...

//-->